WO2012045905A3 - Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama - Google Patents

Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama Download PDF

Info

Publication number
WO2012045905A3
WO2012045905A3 PCT/ES2011/070693 ES2011070693W WO2012045905A3 WO 2012045905 A3 WO2012045905 A3 WO 2012045905A3 ES 2011070693 W ES2011070693 W ES 2011070693W WO 2012045905 A3 WO2012045905 A3 WO 2012045905A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
prognosis
diagnosis
treatment
cancer metastasis
Prior art date
Application number
PCT/ES2011/070693
Other languages
English (en)
French (fr)
Other versions
WO2012045905A2 (es
Inventor
Roger GOMIS CABRÉ
María TARRAGONA SUNYER
Anna ARNAL ESTAPÉ
Milica Pavlovic
Original Assignee
Fundació Privada Institut De Recerca Biomèdica
Fundació Privada Institució Catalana De Recerca I Estudis Avançats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES201031478A external-priority patent/ES2379918B1/es
Priority to CN201810147703.5A priority Critical patent/CN108192972B/zh
Priority to EP19159414.2A priority patent/EP3517630B1/en
Priority to KR1020137011176A priority patent/KR101944555B1/ko
Priority to KR1020197001458A priority patent/KR102240323B1/ko
Priority to EP15180897.9A priority patent/EP3091085B1/en
Priority to BR112013008505-3A priority patent/BR112013008505B1/pt
Priority to MX2013003880A priority patent/MX344315B/es
Application filed by Fundació Privada Institut De Recerca Biomèdica, Fundació Privada Institució Catalana De Recerca I Estudis Avançats filed Critical Fundació Privada Institut De Recerca Biomèdica
Priority to CN201180058347.6A priority patent/CN103339265B/zh
Priority to DK11791605.6T priority patent/DK2626431T3/en
Priority to JP2013532235A priority patent/JP6159254B2/ja
Priority to ES11791605.6T priority patent/ES2562274T3/es
Priority to CA2813674A priority patent/CA2813674C/en
Priority to AU2011311452A priority patent/AU2011311452B2/en
Priority to EP11791605.6A priority patent/EP2626431B1/en
Priority to US13/878,114 priority patent/US10047398B2/en
Publication of WO2012045905A2 publication Critical patent/WO2012045905A2/es
Publication of WO2012045905A3 publication Critical patent/WO2012045905A3/es
Priority to HK14100215.3A priority patent/HK1187377A1/zh
Priority to AU2016266009A priority patent/AU2016266009B2/en
Priority to US16/028,530 priority patent/US11072831B2/en
Priority to AU2019201493A priority patent/AU2019201493B2/en
Priority to AU2021203599A priority patent/AU2021203599A1/en
Priority to US17/385,568 priority patent/US20220049316A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)

Abstract

La presente invención se relaciona con un método para el diagnóstico o el pronóstico de metástasis en cáncer de mama que comprende determinar si el genc-MAF se encuentra amplificado en una muestra de tumor primario. Asimismo, la invención también se relaciona con un método para el diagnóstico o el pronóstico de metástasis en cáncer de mama ER-, así como con un método para determinar la propensión de desarrollar metástasis a hueso frente a metástasis a otros órganos,que comprenden determinar el nivel de expresión del gen c-MAF. Por último, la invención se relaciona con el empleo de un inhibidor de c-MAF como diana terapéutica para el tratamiento de la metástasis del cáncer de mama ER-.
PCT/ES2011/070693 2010-10-06 2011-10-05 Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama WO2012045905A2 (es)

Priority Applications (21)

Application Number Priority Date Filing Date Title
JP2013532235A JP6159254B2 (ja) 2010-10-06 2011-10-05 乳がん転移の診断、予後診断、および処置のための方法
ES11791605.6T ES2562274T3 (es) 2010-10-06 2011-10-05 Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
KR1020137011176A KR101944555B1 (ko) 2010-10-06 2011-10-05 유방암 전이의 진단, 예후 및 치료 방법
KR1020197001458A KR102240323B1 (ko) 2010-10-06 2011-10-05 유방암 전이의 진단, 예후 및 치료 방법
EP15180897.9A EP3091085B1 (en) 2010-10-06 2011-10-05 Method of designing a therapy for breast cancer metastasis
BR112013008505-3A BR112013008505B1 (pt) 2010-10-06 2011-10-05 Usos do nível de expressão do gene c-maf em uma amostra para projetar uma terapia personalizada e diagnosticar a presença e/ou risco de desenvolver metástase óssea em um indivíduo com câncer de mama
MX2013003880A MX344315B (es) 2010-10-06 2011-10-05 Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama.
EP19159414.2A EP3517630B1 (en) 2010-10-06 2011-10-05 Method for the diagnosis, prognosis and treatment of breast cancer metastasis
CN201180058347.6A CN103339265B (zh) 2010-10-06 2011-10-05 用于乳腺癌转移的诊断、预后和治疗的方法
DK11791605.6T DK2626431T3 (en) 2010-10-06 2011-10-05 A process for the diagnosis, prognosis and treatment of breast cancer metastasis
US13/878,114 US10047398B2 (en) 2010-10-06 2011-10-05 Method for the diagnosis, prognosis and treatment of breast cancer metastasis
CN201810147703.5A CN108192972B (zh) 2010-10-06 2011-10-05 用于乳腺癌转移的诊断、预后和治疗的方法
EP11791605.6A EP2626431B1 (en) 2010-10-06 2011-10-05 Method for the diagnosis, prognosis and treatment of breast cancer metastasis
AU2011311452A AU2011311452B2 (en) 2010-10-06 2011-10-05 Method for the diagnosis, prognosis and treatment of breast cancer metastasis
CA2813674A CA2813674C (en) 2010-10-06 2011-10-05 Method for the diagnosis, prognosis and treatment of breast cancer metastasis
HK14100215.3A HK1187377A1 (zh) 2010-10-06 2014-01-09 用於對乳腺癌的轉移進行診斷、預後和治療的方法
AU2016266009A AU2016266009B2 (en) 2010-10-06 2016-11-30 Method for the diagnosis, prognosis and treatment of breast cancer metastasis
US16/028,530 US11072831B2 (en) 2010-10-06 2018-07-06 Method for the diagnosis, prognosis and treatment of breast cancer metastasis
AU2019201493A AU2019201493B2 (en) 2010-10-06 2019-03-05 Method for the diagnosis, prognosis and treatment of breast cancer metastasis
AU2021203599A AU2021203599A1 (en) 2010-10-06 2021-06-02 Method for the diagnosis, prognosis and treatment of breast cancer metastasis
US17/385,568 US20220049316A1 (en) 2010-10-06 2021-07-26 Method for the diagnosis, prognosis and treatment of breast cancer metastasis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ESP201031478 2010-10-06
ES201031478A ES2379918B1 (es) 2010-10-06 2010-10-06 Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama.
ESP201131073 2011-06-27
ES201131073 2011-06-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/878,114 A-371-Of-International US10047398B2 (en) 2010-10-06 2011-10-05 Method for the diagnosis, prognosis and treatment of breast cancer metastasis
US16/028,530 Division US11072831B2 (en) 2010-10-06 2018-07-06 Method for the diagnosis, prognosis and treatment of breast cancer metastasis

Publications (2)

Publication Number Publication Date
WO2012045905A2 WO2012045905A2 (es) 2012-04-12
WO2012045905A3 true WO2012045905A3 (es) 2012-06-21

Family

ID=45099129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2011/070693 WO2012045905A2 (es) 2010-10-06 2011-10-05 Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama

Country Status (14)

Country Link
US (3) US10047398B2 (es)
EP (3) EP3091085B1 (es)
JP (5) JP6159254B2 (es)
KR (2) KR102240323B1 (es)
CN (2) CN108192972B (es)
AR (1) AR083357A1 (es)
AU (4) AU2011311452B2 (es)
BR (1) BR112013008505B1 (es)
CA (1) CA2813674C (es)
DK (2) DK3091085T3 (es)
ES (3) ES2721639T3 (es)
HK (1) HK1187377A1 (es)
MX (1) MX344315B (es)
WO (1) WO2012045905A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108192972B (zh) 2010-10-06 2022-09-09 生物医学研究机构基金会 用于乳腺癌转移的诊断、预后和治疗的方法
EP2650682A1 (en) * 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
ES2705237T3 (es) * 2012-06-06 2019-03-22 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
KR101872965B1 (ko) * 2012-10-12 2018-06-29 인바이오모션 에스.엘. Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법
CN105431548A (zh) * 2013-03-15 2016-03-23 生物医学研究机构基金会 用于癌转移的诊断、预后和治疗的方法
US20160032399A1 (en) * 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
JP6577873B2 (ja) * 2013-03-15 2019-09-18 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） がんの転移の予後診断および処置のための方法
CA2926894A1 (en) * 2013-10-09 2015-04-16 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
EP2933639A1 (en) * 2014-04-16 2015-10-21 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts S100p and Hyaluronic acid as biomarkers for metastatic breast cancer
CN104398506A (zh) * 2014-12-09 2015-03-11 厦门大学 雷奈酸锶在制备预防和治疗腺癌药物中的新用途
JP2017538412A (ja) 2014-12-11 2017-12-28 インバイオモーション エセ．エレ． ヒトｃ−ｍａｆに対する結合メンバー
CN117230193A (zh) 2016-05-25 2023-12-15 生物运动有限公司 基于c-maf状态的乳腺癌治疗性治疗
KR101896558B1 (ko) 2016-11-21 2018-09-07 주식회사 젠큐릭스 유방암 환자의 예후 예측 방법
CN107699619B (zh) * 2017-11-17 2019-02-22 柳超 lncRNA组合物及制备诊断预示Luminal B型乳腺癌骨转移基因诊断试剂盒的用途
CA3082728A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
JP2023079997A (ja) 2021-11-29 2023-06-08 東洋インキＳｃホールディングス株式会社 活性エネルギー線硬化型インクジェットインキ及び印刷物
CN114574577A (zh) * 2022-01-04 2022-06-03 中山大学孙逸仙纪念医院 Mettl16基因及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004920A1 (en) 1985-02-13 1986-08-28 Biotechnology Research Partners, Limited Human metallothionein-ii promoter in mammalian expression system
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
DE4013632A1 (de) * 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
CN1215432A (zh) 1996-04-05 1999-04-28 索尔克生物学研究所 调节外源性基因在哺乳动物系统中表达的激素介导的方法及其相关产物
EP2314695A3 (en) 1996-12-23 2011-12-21 Immunex Corporation Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
KR100688740B1 (ko) 1999-03-15 2007-02-28 액시스 파마슈티컬스 인코포레이티드 프로테아제 억제제로서의 ｎ-시아노메틸 아미드
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
ATE387199T1 (de) 2000-01-06 2008-03-15 Merck Frosst Canada Ltd Neue substanzen und verbindungen als protease- inhibitoren
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
KR20040023630A (ko) 2001-06-26 2004-03-18 아브게닉스, 인크. Ｏｐｇｌ에 결합하는 항체
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
KR100485271B1 (ko) 2002-01-16 2005-04-27 메타볼랩(주) 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
DE10235624A1 (de) 2002-08-02 2004-02-19 Aventis Pharma Deutschland Gmbh Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben
US20050060771A1 (en) 2003-09-11 2005-03-17 Farmer Andrew Alan siRNA encoding constructs and methods for using the same
EP1668354A2 (en) 2003-09-24 2006-06-14 Oncotherapy Science, Inc. Method of diagnosing breast cancer
AU2003286499A1 (en) 2003-10-17 2004-06-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
WO2005060722A2 (en) 2003-12-18 2005-07-07 President And Fellows Of Hardvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
CA2558808A1 (en) 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
WO2006012221A2 (en) 2004-06-25 2006-02-02 The Regents Of The University Of California Target cell-specific short interfering rna and methods of use thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US9127302B2 (en) 2005-09-20 2015-09-08 Janssen Diagnostics, Llc System for the detection and enumeration of suspect target cells in a mixed cell population
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
JP2009509966A (ja) 2005-09-26 2009-03-12 ノバルティス アクチエンゲゼルシャフト 骨転移に関連した分子マーカー
WO2007069090A2 (en) 2005-12-06 2007-06-21 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
ES2663512T3 (es) 2007-05-24 2018-04-13 Ablynx N.V. Secuencias de aminoácidos dirigidas contra RANK-L y polipéptidos que comprenden las mismas para el tratamiento de enfermedades y trastornos óseos
JP5350369B2 (ja) 2007-05-31 2013-11-27 ダコ デンマーク アクティーゼルスカブ 乳癌治療および予後におけるｅｓｒコピー数変化の利用方法
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
US20110123617A1 (en) 2007-10-18 2011-05-26 University Health Network Clioquinol for the treatment of hematological malignancies
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
US20110144155A1 (en) 2008-06-06 2011-06-16 Schimmer Aaron D 8-hydroxyquinoline derivatives for the treatment of hematological malignancies
ES2338843B1 (es) 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
SG10201507044PA (en) 2009-05-29 2015-10-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2486149B1 (en) 2009-08-06 2015-06-17 John Wayne Cancer Institute Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
CN108192972B (zh) 2010-10-06 2022-09-09 生物医学研究机构基金会 用于乳腺癌转移的诊断、预后和治疗的方法
CA2826657A1 (en) 2011-02-04 2012-08-09 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
CA2830240A1 (en) 2011-03-15 2012-09-20 The University Of North Carolina At Chapell Hill Methods of treating breast cancer with anthracycline therapy
US20140303133A1 (en) 2011-11-18 2014-10-09 Vanderbilt University Markers of Triple-Negative Breast Cancer And Uses Thereof
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
ES2705237T3 (es) 2012-06-06 2019-03-22 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
KR101872965B1 (ko) 2012-10-12 2018-06-29 인바이오모션 에스.엘. Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법
JP6577873B2 (ja) 2013-03-15 2019-09-18 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） がんの転移の予後診断および処置のための方法
CN105431548A (zh) 2013-03-15 2016-03-23 生物医学研究机构基金会 用于癌转移的诊断、预后和治疗的方法
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
CA2926894A1 (en) 2013-10-09 2015-04-16 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
JP2017538412A (ja) 2014-12-11 2017-12-28 インバイオモーション エセ．エレ． ヒトｃ−ｍａｆに対する結合メンバー
CN117230193A (zh) 2016-05-25 2023-12-15 生物运动有限公司 基于c-maf状态的乳腺癌治疗性治疗
CA3082728A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRUFSKY ADAM M: "The evolving role of bone-conserving therapy in patients with breast cancer.", SEMINARS IN ONCOLOGY JUN 2010 LNKD- PUBMED:20682367, vol. 37 Suppl 1, June 2010 (2010-06-01), pages S12 - S19, XP009156251, ISSN: 1532-8708 *
NATHALIE ROCQUES ET AL: "GSK-3-Mediated Phosphorylation Enhances Maf-Transforming Activity", MOLECULAR CELL, vol. 28, no. 4, 1 November 2007 (2007-11-01), pages 584 - 597, XP055018587, ISSN: 1097-2765, DOI: 10.1016/j.molcel.2007.11.009 *

Also Published As

Publication number Publication date
AU2019201493A1 (en) 2019-03-28
CN103339265A (zh) 2013-10-02
JP2019195340A (ja) 2019-11-14
DK3091085T3 (da) 2019-05-06
EP3517630B1 (en) 2022-01-19
ES2721639T3 (es) 2019-08-02
CA2813674C (en) 2020-11-24
CN108192972B (zh) 2022-09-09
AU2021203599A1 (en) 2021-07-01
CN108192972A (zh) 2018-06-22
HK1187377A1 (zh) 2014-04-04
KR20140071946A (ko) 2014-06-12
JP2017104115A (ja) 2017-06-15
EP3091085A1 (en) 2016-11-09
DK2626431T3 (en) 2015-12-21
ES2562274T3 (es) 2016-03-03
AR083357A1 (es) 2013-02-21
KR101944555B1 (ko) 2019-02-01
AU2019201493B2 (en) 2021-03-11
US10047398B2 (en) 2018-08-14
EP2626431B1 (en) 2015-09-16
KR102240323B1 (ko) 2021-04-14
US20140057796A1 (en) 2014-02-27
BR112013008505A2 (pt) 2016-07-05
CA2813674A1 (en) 2012-04-12
CN103339265B (zh) 2018-03-30
ES2911505T3 (es) 2022-05-19
AU2011311452A1 (en) 2013-05-09
JP2013541339A (ja) 2013-11-14
AU2011311452B2 (en) 2016-09-01
KR20190009835A (ko) 2019-01-29
EP3091085B1 (en) 2019-02-27
WO2012045905A2 (es) 2012-04-12
US11072831B2 (en) 2021-07-27
US20220049316A1 (en) 2022-02-17
EP3517630A1 (en) 2019-07-31
JP2018099132A (ja) 2018-06-28
MX2013003880A (es) 2013-12-02
AU2016266009B2 (en) 2018-12-06
JP6946385B2 (ja) 2021-10-06
JP6571698B2 (ja) 2019-09-04
BR112013008505B1 (pt) 2023-01-24
AU2016266009A1 (en) 2016-12-15
EP2626431A2 (en) 2013-08-14
JP2021192636A (ja) 2021-12-23
JP6159254B2 (ja) 2017-07-12
MX344315B (es) 2016-12-13
US20190169693A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
WO2012045905A3 (es) Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
WO2015052583A3 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
MY182773A (en) Method for indicating a presence or non-presence of aggressive prostate cancer
MX2009002936A (es) Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf.
WO2010091049A3 (en) Diagnosis and treatment of cancer
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
NZ719474A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2013009655A3 (en) Uses of labeled hsp90 inhibitors
MX357429B (es) Predictores para el tratamiento del cáncer.
WO2011134670A3 (en) Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
MY148542A (en) A method for the assessment of cancer in a biological sample obtained from a subject
WO2012129517A3 (en) Evaluating protein expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
WO2013011153A3 (en) Method for the prognosis and treatment of metastasis in breast cancer
WO2009126966A3 (en) Genetic markers indicating biological response to a plk1 kinase inhibitor
WO2013040071A3 (en) Sperm protein as a detection biomarker of early stage ovarian cancer
MX2014002307A (es) Metodo para predecir el riesgo de hipertension asociado a la terapia antiangiogenesis.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11791605

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2813674

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013532235

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/003880

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137011176

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011791605

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011311452

Country of ref document: AU

Date of ref document: 20111005

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13878114

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013008505

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013008505

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130408